IMUX - NASDAQ

Immunic, Inc.

IMUX·NASDAQ

$14.66

+2.3%

HealthcareBiotechnology

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$144.72M

EPS-6.2400

P/E Ratio-2.35

Earnings Date08/06/2026

0.00

Revenue

3Y-

5Y-

10Y-100.0%

-97.17M

Net Income

-3%

3Y-19.0%

5Y+121.0%

10Y+137.0%

-85.81M

Operating Cash Flow

3Y+32.0%

5Y+86.0%

10Y+140.0%

Immunic, Inc. Profit Bridge

IMUX · NASDAQ

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (168.00K)

Gross Profit-168.00K

Operating Expenses

Operating Expenses (103.23M)

Operating Income-103.23M

Other Income & Taxes

Interest Expense (0.00)

Other Income/Expense6.06M

Pretax Income-97.17M

Income Tax (0.00)

Net Income-97.17M

Net Income

-97.17M

Profitability Analysis

Immunic, Inc. Income Statement

IMUX • NASDAQ

Immunic, Inc. Income Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011
REVENUE
Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3K	0.0	0.0	0.0	0.0	0.0
GROSS PROFIT
Cost of Revenue	(168K)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(50K)	(15K)	(998K)	(1.8M)	(1.3M)	(0.0)	(0.0)	(0.0)	(0.0)
Gross Profit	-168K	0.0	0.0	0.0	0.0	0.0	-50K	-15K	-998K	-1.8M	-1.3M	0.0	0.0	0.0	0.0
OPERATING INCOME
Operating Expenses	(103.2M)	(98.1M)	(99.2M)	(119.5M)	(91.7M)	(49M)	(37M)	(38.4M)	(52.7M)	(41.3M)	(52.1M)	(50.3M)	(31.4M)	(9.6M)	(8.6M)
Selling, General & Administrative	(21.2M)	(18M)	(16M)	(15.3M)	(13.3M)	(10.3M)	(14.5M)	(13.6M)	(13.3M)	(11.2M)	(12.3M)	(10.9M)	(9.6M)	(4.5M)	(3.1M)
Research & Development	(82M)	(80M)	(83.2M)	(71.3M)	(61.1M)	(38.6M)	(22.5M)	(24.8M)	(39.3M)	(30M)	(39.8M)	(39.5M)	(21.8M)	(5.1M)	(5.5M)
Operating Income	-103.2M	-98.1M	-99.2M	-119.5M	-91.7M	-49M	-37M	-42M	-52.7M	-41.3M	-52.1M	-50.3M	-31.4M	-9.6M	-8.6M
PRE-TAX INCOME
Interest Expense	(0.0)	(0.0)	(0.0)	(1M)	(0.0)	(0.0)	(107K)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(413K)	(9.2M)
Net Interest Income	1M	3.4M	3.1M	0.0	66K	58K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-409K	-9.2M
Other Expenses	(0.0)	(0.0)	(0.0)	(33M)	(17.3M)	(0.0)	(0.0)	(28K)	(0.0)	(297K)	(97K)	(0.0)	(0.0)	(0.0)	(0.0)
Total Other Income Expenses Net	6.1M	-2.5M	5.6M	-919K	-1.3M	5M	2.1M	455K	577K	297K	97K	2.7M	-1.3M	-40K	2.7M
Income Before Tax	-97.2M	-100.5M	-93.6M	-120.4M	-92.9M	-44M	-34.9M	-41.5M	-52.1M	-41M	-52M	-47.7M	-32.7M	-6.7M	-5.9M
NET INCOME
Income Tax Expense	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-107K	(549K)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(413K)	(0.0)
Net Income	-97.2M	-100.5M	-93.6M	-120.4M	-92.9M	-44M	-34.8M	-41.5M	-52.1M	-41M	-52M	-47.7M	-32.7M	-6.7M	-5.9M

SEC Filings

IMUX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
DEF 14A DEF 14A 2026 N/A	May 29, 2026	June 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 28, 2026	May 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 27, 2026	May 22, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 19, 2026	May 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
S-3/A S-3/A (Amended) N/A	April 30, 2026	April 30, 2026		View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 23, 2026	April 22, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	April 22, 2026	December 31, 2025	2025	View Filing

Showing 1 to 10 of 264 filings

Related Guides

Blog Categories

Continue your IMUX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.